美股市场个股详情

NRSN NeuroSense Therapeutics

添加自选

1.330
+0.060+4.72%

收盘价 05/03 16:00 (美东)

1.360
+0.030+2.26%

盘后 17:55 (美东)

2471.41万总市值-1602市盈率TTM

NeuroSense Therapeutics股票讨论区

登录发表评论

Trytosaveabit

04/22 20:36

A bit more

$NeuroSense Therapeutics(NRSN.US)$ Neurosense Therapeutics: Study Expected to Reveal Safety of Primec in Ad, and Shed Light on Efficacy, Biological Activity of Combination Therapy

Trytosaveabit

04/22 20:31

Update

$NeuroSense Therapeutics(NRSN.US)$ Neurosense and Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Jaguar8

04/18 20:31

$NeuroSense Therapeutics(NRSN.US)$
NEWS
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS
Statistically significant slowing of disease progression by 37% in the per-protocol population
Validation of topline data by the American Academy of Neurology
Positive trend towards impacting Neurofilament biomarker level...

Trytosaveabit

04/11 07:26

Update

$NeuroSense Therapeutics(NRSN.US)$ NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire· 8 mins ago
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor fo...

JACK454

02/28 04:18

$NeuroSense Therapeutics(NRSN.US)$ Truly being BLESSED

Stock Region

02/23 00:16

NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results.

NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results.
In a pivotal development for the treatment of Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive results from its Phase 2b PARADIGM trial. The company's lead drug candidate, PrimeC, demonstrated substantial clinical efficacy, marking a significant milest...

Trytosaveabit

02/21 21:36

Update

$NeuroSense Therapeutics(NRSN.US)$ NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
6 MINUTES AGO, 8:30 AM EST
VIA PR NEWSWIRE
• PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
• Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
• Further analysis of PARADIGM is on track with neurofilament resu...

Trytosaveabit

01/30 21:37

Update

$NeuroSense Therapeutics(NRSN.US)$ NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
ACCESSWIRE 30-Jan-2024 8:32 AM

JACK454

01/06 04:57

$NeuroSense Therapeutics(NRSN.US)$ my apologies 44 dollars still doesn’t make sense. why don’t they let them buy them at that price of they want them. would teach them to stop bidding bullshit

JACK454

01/06 04:55

$NeuroSense Therapeutics(NRSN.US)$ how is bid all the way up to 70 dollars don’t make sense!!!

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度